FORM PTO 1449 (modified)			Atty. Docket No. X-10822B	Serial	NO 10	18116	46	
INFORMATI IN AN APP		SCLOSURE CITATI	ON	Applicant Suad Efendic				
				Filing Date 3/29/ 2004	Group	1646	<u>'</u>	
	-		U.S. P.	ATENT DOCUMENTS				
Examiner Initial		Document Number	Date	Name	Class	Sub- class	Filing If Approp	
4	AA	5,202,239	04/13/93	Tarnowskida)	Appropr	1800
	AB	5,631,224	05/1997	Efendic, et al.				
	AC	6,006,753	12/1999	Efendic			1	
	AD	5,614,492	03/1997	Habener			1	
	AE	5,118,666	06/1992	Habener				
18e	AP	5,120,712	06/1992	Habener				
<i>-</i>						-		
	L		PORBIG	N PATENT DOCUMENTS	<u></u>			
		Document Number	Date	Country	Class	Sub- class	Transla	ation
		112 25 /25 22		7 Sweden			yes X	no
1	BA	WO 95/05848	45.030		1			
	BB	WO 96/29342	96,69				х	
	BC	EP 700995	96.03.13					·
1/20	BD	WO 92/02550	92,02.20	O EPO			·	
					1	'		
	OTH	ER DOCUMENTS (Inc	luding Au	thor, Title, Date, Pert	inent Pa	ges, Etc	.)	
84	CA	Followed b	y Subcuta ardial In	JACC, "Randomized Trial cancer insulin Treatment of arction (DIGAMI Study): 1995.	in Diabe	on Mor	tality a	t 1
	СВ	Year", 26(1):57-65, 1995. Malmberg, et al., European Heart Journal, "Effects of Insulin Treatment on Cause-Specific One-Year Mortality and Morbidity in Diabetic Patients with Acute Myocardial Infarction", 17:1337-1344, 1996.						
	cc	Fava, et a in Diabeti	l., Diabe c Patient	etic Medicine, "The Progr is with Acute Myocardial	Infarct:	ion", 13	:80-83,	1996.
15	CD	l of Stress	Hyperalyc	itish Medical Journal, "I caemia in Non-Diabetic Pa 17-922, 1986.	Determina stients	ants and with Myo	Importa cardial	nce
EXAMINER		you Che	In	DATE CONSIDERED	4/24/			
IMPEP 609:	Draw	ial if citation of line through cital the line through cital the line is a second communication of the line is a second cital through the line is a second cital throught the line is a second cital throught through the line is a second cital throught throught the line is a second cital throught throught through the line is a second cital throught throught through the line is a second cital throught through the line is a second cital throught through the line is a second cital through the line is a second cital through the line is a second cital through the line is	ation if a	d, whether or not citati not in conformance and n the applicant.	on is in ot consi	conform dered.	nance wit	copy

		Atty. Docket No. X-10822B	Serial No 10/811,646
INFORMATION DISCLOS IN AN APPLICATION	SURE CITATION	Applicant Suad Efendic	
		Filing Date 3/29/64	Group 1646
& CE		Myocardial Infarction i	Cardiology, "Hyperglycemia and In Patients Without Diabetes
CF	O'Sullivan, et al., With Pasting Hyperg 14(8)758-760, 1991.	Diabetes Care, "In-Hos glycemia After First Myo	
CG	Level: A Determinan	it for In-hospital Outco	cine, "Pasting Blood Sugar me in Patients with First Intolerance", 22(3):291-295,
CH .	476, 1992.		ow and Metabolism, 12:469-
CI	Barbash, et al, JAC	C, 22(3):707-13, 1993.	
Ci	Bell, Diabetes Care	2, 17(3):213-219, 1994.	
СК	Broderick, et al.,	Stroke, 26:484-487, 199	95.
CL	Derouesné, et al.,	Acta. Neurol. Scand., 8	37:361-366, 1993.
. CM	Chukwuma, et al, J.	. Diab. Comp., 7:250-262	2, 1993.
CN	Davi, et al., The N 1990.	New England Journal of N	Medicine, 322(25):1769-74,
co	Dhanvantari, et al.	., Molecular Endocrinolo	pgy, 10:342-355, 1996.
СР	Dietrich, et al., S	Stroke, 24:111-116, 1993	
co	Dimlich, et al., St	croke, 23:1145-1153, 195	92.
CR	De Falco, et al., 3 144(3):233-239, 199		urologie und Psychiatric Band,
CS	Pang, et al., Chine	ese Med. J., 108(4):259-	-261, 1995.
CT	Fehmann, et al., Mo 1992.	olecular and Cellular Er	ndocrinology, 85:C39-C44,
CU	Granger, et al., Ar	merican College of Card	iology, 21(4):920-925, 1993.
cv	Grines, et al., The	e New England Journal of	f Medicine, 328(10):673-679,
CW	Gundersen, et al.,	Diabetes Care, 6(3):285	5-290, 1983.
(CX	Hamann, et al., Exp	o. Clin. Endocrinol. & l	Diabetes, 104:293-300, 1996.
CY	Hamsten, J. of Int	. Med., 236:736:1-3, 199	94.
se cz	Janghorbani, et al	., J. Clin. Epidemiol.,	47(4):397-405, 1994.
EXAMINER Lygon	clase	DATE CONSIDERED	4/24/06
*EXAMINER: Initial is MPEP 609; Draw line of this form with ne	through citation if	not in conformance and	ion is in conformance with not considered. Include copy

FORM PTO	1449 (mo	dified)	Atty. Docket No. X-10822B	Serial No 10/8/1,646
	ON DISCL	OSURE CITATION	Applicant Suad Efendic	
			Filing Date 3/29/04	Group 1646
Re	CAA	Karlson, et al.,	Diabetic Medicine, 10:4	49-454, 1993.
1	CAB	Kiers, et al., J.	Neurol., Neurosurg., a	nd Psych., 55:263-270, 1992.
	CAC	Kittaka, et al.,	Stroke, 27:712-719, 1990	6.
	CAD	Van Kooten, et al	., Stroke, 24:1129-1132	, 1993.
	CAE	Pibrinolytic Thera		llaborative Group, The Lancet,
	CAF	Lehto, et al., St.	roke, 27:63-68, 1996.	
	CAG	Malmberg, et al.,	European Heart Journal	, 9:259-264, 1988.
	CAH	Malmberg, et.al.,	European Heart Journal	, 10:423-428, 1989.
	CAI	Wass, et al., May	o Clin. Proc., 71:801-8	12, 1996.
	CAJ	Wheeler, et al.,	Endocrinology, 133(1):5	7-62, 1993.
	CAK	Wingard, et al.,	Diabetes Care, 16(7):10	22-1025, 1993.
	CAL	Wolffenbuttel, et	al., Drugs, 50(2):263-	288, 1995.
	CAM	Brest, A.N ed., F	. A. Davis Company	in Cardiovascular Clinics,
	CAN	Branched Chain Am Thoracic and Card pages 98-107.	ino Acids Soon After Ca iovascular Surgery, Jan	n on Myocardial Uptake of rdiac Operations." <i>Journal of</i> uary 1992, Vol. 103, No. 1,
H	CAO	Slovenski, S., et	al., "Coronary Heart D tica, 1995, Vol. 24, No	isease and Diabetes Mellitus." . 3, pages 91-101.
				·
EXAMINER	~ / /	a Uki	DATE_CONSIDERED	9/29/06
*EXAMINER MPEP 609;	Initial Draw line	if citation consider through citation if	red, whether or not cital not in conformance and	tion is in conformance with i not considered. Include copy

FORM PTO 1449 (modified)	Atty. Docket No. X-10822B	Serial No 10/811,646
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant EFENDIC, Suad	
	Application Date March 29, 2004	Group Art Unit 1646

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
Initials*	No. ¹	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Pages or Relevant Figures Appear
18	AK	US 6,982,248	01-03-2006	Coolidge etal	
gr	AL	US 6,248,725	06-19-2001	Alison et al	
ge	AM	US 10/091,258		Hathaway etal	
Sp	AN	US 11/198,527		- Hathway etal	
	AO	-US			V

Examiner Initials*	Cite No.1	Foreign Patent Document		Name of Patentee or Applicant of Cited	Pages, Columns, Lines, Where	T ⁶
	No.	Country Code ³ -Number ⁴⁻ Kind Code5 (if known)	Publication Date MM-DD-YYYY	Document	Relevant Passages or Relevant Figures Appear	
	BJ					
,	BK					
	<u> </u>	NON PAT	ENT LITERAT	TURE DOCUME	ENTS	1
Examiner Initials*	Cite No. 1	Include name of the author	in CAPITAL LETTERS), title of the article (when , etc.), date, page(s), volur	ENTS appropriate), title of the item ne-issue number(s) publisher.	т6
		Include name of the author (book, magazine, journal, see REPORT OF PROCE COOLIDGE and MAFEFENDIC, Application	in CAPITAL LETTERS rial, symposium, catalog city and/or count EDINGS in the telep RIO EHLERS, Junio on No. 09/400,802, S strative Patent Judg), title of the article (when , etc.), date, page(s), volur ry where published. ohonic conference re: or Party, Patent No. 6 Senior Party; Patent I e Michael P. Tierney	appropriate), title of the item ne-issue number(s) publisher. THOMAS ,284,725 vs SUAD nterference 105,457 , held on Monday, July	т6

Examiner Signature	lygan	dur	Date Considered	4/	11/	2007	
*FYAMINER: Initi	al if reference concillered, whether or	not citation is in conformance with MPEP 609 D	aw line through citation if not	in conformanc	e and not o	onsidered. Include conv.of	

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.